{
  "schemaVersion": 1,
  "organisationId": "O-adcbd736b1264a47ba15033e71317f8a",
  "slug": "cg-oncology-inc",
  "name": "CG Oncology, Inc.",
  "updatedAt": "2026-10-02T15:42:30.769865Z",
  "sections": [
    {
      "type": "OVERVIEW",
      "text": "CG Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for bladder cancer, particularly high- and intermediate-risk non-muscle-invasive bladder cancer. Its lead investigational candidate, cretostimogene grenadenorepvec, is an oncolytic immunotherapy intended to attack cancer cells and stimulate an anti-tumor immune response; it is being studied in Phase 3 and Phase 2 programs and is not an approved product. [P53564465][P119008555][P97832655][P47221123]\n\nThe company’s stated mission is to develop bladder-sparing therapeutics for people with bladder cancer, with a vision centered on dignity and quality of life for people affected by urologic cancers. [https://cgoncology.com/careers/] CG Oncology is building U.S. commercial capabilities and has licensing arrangements covering markets outside the United States. [P29760096][P2572601]\n\nAs a scale indicator, CG Oncology reported 142 employees at December 31, 2025. For the six months ended June 30, 2026, it reported $2.240 million in total revenue, primarily classified as commercial and development revenue. [https://ir.cgoncology.com/sec-filings/sec-filing/10-k/0001193125-26-079498][T16902607]\n[P53564465][P119008555][P97832655][P47221123][https://cgoncology.com/careers/][P29760096][P2572601][https://ir.cgoncology.com/sec-filings/sec-filing/10-k/0001193125-26-079498][T16902607][https://cgoncology.com/careers/][https://ir.cgoncology.com/sec-filings/sec-filing/10-k/0001193125-26-079498]",
      "updatedAt": "2026-10-02T15:42:30.769865Z"
    },
    {
      "type": "PRODUCTS",
      "text": "CG Oncology’s lead product candidate is cretostimogene grenadenorepvec, an investigational intravesical oncolytic immunotherapy for bladder cancer. It is an engineered, replication-competent adenovirus: its E2F-1 promoter is designed to favor replication and lysis in tumor cells with Rb–E2F pathway alterations, while an encoded GM-CSF gene is intended to stimulate anti-tumor immunity. [P117659139][P47969137][https://cgoncology.com/pipeline/]\n\nCretostimogene is being evaluated in high-risk, BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC), including as monotherapy in the Phase 3 BOND-003 study, and as adjuvant therapy after tumor resection for intermediate-risk NMIBC in Phase 3 PIVOT-006. The Phase 2 CORE-008 program includes BCG-naïve and BCG-exposed cohorts, as well as a cohort combining cretostimogene with gemcitabine. [P147679845][P147679847][P147679848]\n\nThe company does not identify a separate marketed-product or commercial-services portfolio, and reported no revenue from cretostimogene product sales through June 30, 2026. Its disclosed Kissei license concerns development and commercialization of cretostimogene with DDM in specified Asian territories; Kissei is responsible for commercialization there, and CG Oncology supplies the licensed product. No product-sales or product-performance percentage is disclosed. [P147679970][P147679744]\n[P117659139][P47969137][https://cgoncology.com/pipeline/][P147679845][P147679847][P147679848][P147679970][P147679744][https://cgoncology.com/pipeline/]",
      "updatedAt": "2026-10-02T15:42:30.769865Z"
    },
    {
      "type": "GEOGRAPHY",
      "text": "CG Oncology’s current contact page lists its corporate headquarters in Dallas, Texas. Its 2025 year-end filing identified Irvine, California, as the principal executive office and said a Dallas office lease would begin in 2026. The filing also lists leased offices in Emeryville, California, and Branchburg, New Jersey, as well as an office/manufacturing/warehouse lease whose location is not specified in the cited disclosure. [https://cgoncology.com/contact/][P82693982]\n\nThe company has reported a global clinical-trial footprint: its BOND-003 Cohort C Phase 3 trial included participants in North America, Australia, and Asia-Pacific. [https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-publication-pivotal-phase-3-bond-003] The 2026 Q2 report does not provide geographic revenue or asset figures, and no employee distribution by location was identified in the reviewed disclosures. [P147679761]\n[P82693982][P147679761][https://cgoncology.com/contact/][https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-publication-pivotal-phase-3-bond-003]",
      "updatedAt": "2026-10-02T15:42:30.769865Z"
    },
    {
      "type": "SEGMENTS",
      "text": "CG Oncology reports one operating segment: the consolidated company, with no separately reported product, therapeutic-area, or geographic segments. The CEO, as chief operating decision maker, assesses performance and allocates resources using consolidated financial information; segment assets are not reviewed. The single segment therefore represents 100% of the reported business, but the company does not disclose segment-level revenue or asset contributions. [P147679761][P59147757] Its development work includes cretostimogene for bladder-cancer indications, including non-muscle-invasive bladder cancer; this is a business focus, not a separate reportable segment. [P104907045]\n[P147679761][P59147757][P104907045]",
      "updatedAt": "2026-10-02T15:42:30.769865Z"
    },
    {
      "type": "HISTORY",
      "text": "CG Oncology was founded in California as Cold Genesys, Inc. on September 24, 2010. In 2014, it announced Series A financing to support development of CG0070, its investigational bladder-cancer therapy. [P164330910][https://ir.cgoncology.com/news-releases/news-release-details/1357-million-series-round-financing-accelerate-its-ongoing-phase]\n\nThe company reincorporated in Delaware in 2017 and adopted the name CG Oncology, Inc. in 2020; that year it also announced a regional licensing and commercialization agreement with Kissei for CG0070. [P164330910][https://cgoncology.com/news-media/cg-oncology-announces-9/] It advanced the therapy into Phase 3 trials, reporting BOND-003 enrollment completion in 2023 and receiving FDA Fast Track and Breakthrough Therapy designations for cretostimogene in December of that year. [https://cgoncology.com/news-media/cg-oncology-completes/][https://cgoncology.com/news-media/cg-oncology-receives/]\n\nIn January 2024, CG Oncology completed its initial public offering, raising $437 million gross. It continued expanding clinical development that year, including initiating Phase 2 CORE-008 Cohort A and reporting topline BOND-003 results in December. [https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-closing-initial-public-offering-and-full][P164330892][P164330870]\n[P164330910][P164330892][P164330870][https://ir.cgoncology.com/news-releases/news-release-details/1357-million-series-round-financing-accelerate-its-ongoing-phase][https://cgoncology.com/news-media/cg-oncology-announces-9/][https://cgoncology.com/news-media/cg-oncology-completes/][https://cgoncology.com/news-media/cg-oncology-receives/][https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-closing-initial-public-offering-and-full]",
      "updatedAt": "2026-10-02T15:42:30.769865Z"
    }
  ],
  "sources": [
    {
      "id": "P53564465",
      "href": "https://app.finbar.com/go?id=P53564465",
      "label": "CG Oncology, Inc. — Full financial report (2025 Y)",
      "documentId": "D-8dce2ba290fc46b39a729a7757754010"
    },
    {
      "id": "P119008555",
      "href": "https://app.finbar.com/go?id=P119008555",
      "label": "CG Oncology, Inc. — Full financial report (2025 Y)",
      "documentId": "D-8dce2ba290fc46b39a729a7757754010"
    },
    {
      "id": "P97832655",
      "href": "https://app.finbar.com/go?id=P97832655",
      "label": "CG Oncology, Inc. — Full financial report (2025 Y)",
      "documentId": "D-8dce2ba290fc46b39a729a7757754010"
    },
    {
      "id": "P47221123",
      "href": "https://app.finbar.com/go?id=P47221123",
      "label": "CG Oncology, Inc. — Full financial report (2025 Y)",
      "documentId": "D-8dce2ba290fc46b39a729a7757754010"
    },
    {
      "id": "https://cgoncology.com/careers/",
      "href": "https://cgoncology.com/careers/",
      "label": "cgoncology.com"
    },
    {
      "id": "P29760096",
      "href": "https://app.finbar.com/go?id=P29760096",
      "label": "CG Oncology, Inc. — Full financial report (2025 Y)",
      "documentId": "D-8dce2ba290fc46b39a729a7757754010"
    },
    {
      "id": "P2572601",
      "href": "https://app.finbar.com/go?id=P2572601",
      "label": "CG Oncology, Inc. — Full financial report (2026 Q 1)",
      "documentId": "D-e26357c9bbc046018948bdca98783fd6"
    },
    {
      "id": "https://ir.cgoncology.com/sec-filings/sec-filing/10-k/0001193125-26-079498",
      "href": "https://ir.cgoncology.com/sec-filings/sec-filing/10-k/0001193125-26-079498",
      "label": "ir.cgoncology.com"
    },
    {
      "id": "T16902607",
      "href": "https://app.finbar.com/go?id=T16902607",
      "label": "CG Oncology, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d388614583604edcbc362ed774d474d6"
    },
    {
      "id": "P117659139",
      "href": "https://app.finbar.com/go?id=P117659139",
      "label": "CG Oncology, Inc. — Full financial report (2025 Y)",
      "documentId": "D-8dce2ba290fc46b39a729a7757754010"
    },
    {
      "id": "P47969137",
      "href": "https://app.finbar.com/go?id=P47969137",
      "label": "CG Oncology, Inc. — Full financial report (2025 Y)",
      "documentId": "D-8dce2ba290fc46b39a729a7757754010"
    },
    {
      "id": "https://cgoncology.com/pipeline/",
      "href": "https://cgoncology.com/pipeline/",
      "label": "cgoncology.com"
    },
    {
      "id": "P147679845",
      "href": "https://app.finbar.com/go?id=P147679845",
      "label": "CG Oncology, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d388614583604edcbc362ed774d474d6"
    },
    {
      "id": "P147679847",
      "href": "https://app.finbar.com/go?id=P147679847",
      "label": "CG Oncology, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d388614583604edcbc362ed774d474d6"
    },
    {
      "id": "P147679848",
      "href": "https://app.finbar.com/go?id=P147679848",
      "label": "CG Oncology, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d388614583604edcbc362ed774d474d6"
    },
    {
      "id": "P147679970",
      "href": "https://app.finbar.com/go?id=P147679970",
      "label": "CG Oncology, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d388614583604edcbc362ed774d474d6"
    },
    {
      "id": "P147679744",
      "href": "https://app.finbar.com/go?id=P147679744",
      "label": "CG Oncology, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d388614583604edcbc362ed774d474d6"
    },
    {
      "id": "https://cgoncology.com/contact/",
      "href": "https://cgoncology.com/contact/",
      "label": "cgoncology.com"
    },
    {
      "id": "P82693982",
      "href": "https://app.finbar.com/go?id=P82693982",
      "label": "CG Oncology, Inc. — Full financial report (2025 Y)",
      "documentId": "D-8dce2ba290fc46b39a729a7757754010"
    },
    {
      "id": "https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-publication-pivotal-phase-3-bond-003",
      "href": "https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-publication-pivotal-phase-3-bond-003",
      "label": "ir.cgoncology.com"
    },
    {
      "id": "P147679761",
      "href": "https://app.finbar.com/go?id=P147679761",
      "label": "CG Oncology, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d388614583604edcbc362ed774d474d6"
    },
    {
      "id": "P59147757",
      "href": "https://app.finbar.com/go?id=P59147757",
      "label": "CG Oncology, Inc. — Full financial report (2025 Y)",
      "documentId": "D-8dce2ba290fc46b39a729a7757754010"
    },
    {
      "id": "P104907045",
      "href": "https://app.finbar.com/go?id=P104907045",
      "label": "CG Oncology, Inc. — Full financial report (2025 Y)",
      "documentId": "D-8dce2ba290fc46b39a729a7757754010"
    },
    {
      "id": "P164330910",
      "href": "https://app.finbar.com/go?id=P164330910",
      "label": "CG Oncology, Inc. — Ipo (2024 O)",
      "documentId": "D-bf72a8a8ffc04f20a909a9c98540099b"
    },
    {
      "id": "https://ir.cgoncology.com/news-releases/news-release-details/1357-million-series-round-financing-accelerate-its-ongoing-phase",
      "href": "https://ir.cgoncology.com/news-releases/news-release-details/1357-million-series-round-financing-accelerate-its-ongoing-phase",
      "label": "ir.cgoncology.com"
    },
    {
      "id": "https://cgoncology.com/news-media/cg-oncology-announces-9/",
      "href": "https://cgoncology.com/news-media/cg-oncology-announces-9/",
      "label": "cgoncology.com"
    },
    {
      "id": "https://cgoncology.com/news-media/cg-oncology-completes/",
      "href": "https://cgoncology.com/news-media/cg-oncology-completes/",
      "label": "cgoncology.com"
    },
    {
      "id": "https://cgoncology.com/news-media/cg-oncology-receives/",
      "href": "https://cgoncology.com/news-media/cg-oncology-receives/",
      "label": "cgoncology.com"
    },
    {
      "id": "https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-closing-initial-public-offering-and-full",
      "href": "https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-closing-initial-public-offering-and-full",
      "label": "ir.cgoncology.com"
    },
    {
      "id": "P164330892",
      "href": "https://app.finbar.com/go?id=P164330892",
      "label": "CG Oncology, Inc. — Ipo (2024 O)",
      "documentId": "D-bf72a8a8ffc04f20a909a9c98540099b"
    },
    {
      "id": "P164330870",
      "href": "https://app.finbar.com/go?id=P164330870",
      "label": "CG Oncology, Inc. — Ipo (2024 O)",
      "documentId": "D-bf72a8a8ffc04f20a909a9c98540099b"
    }
  ]
}